TIDMMXC
RNS Number : 8135Y
MGC Pharmaceuticals Limited
17 May 2021
17 May 2021 MGC Pharmaceuticals Ltd.
ASX Code: MGC Pharma Patent Application for CimetrA(TM) Successfully
MXC Submitted to European IP Office
LSE Code:
MXC
Key Highlights :
-- The patent application for CimetrA(TM) , the Investigational
Medicinal Product (IMP) assigned to MGC Pharma, has been accepted
by the Slovenian Intellectual Property Office (SIPO).
-- CimetrA(TM) has been designed for multiple therapeutic
applications including acute and chronic inflammation, COVID-19 and
variants of influenza, autoimmune diseases, adverse events
resulting from the various forms of cancer therapy, and the
promotion of an immune response to bacterial, viral, fungal and
parasitic infections, highlighting its versatility as a
medicine.
-- MGC Pharma has successfully submitted its patent application
to, and was accepted by SIPO on 5 May 2021 (file number:
P-202100096) which is the priority date for the patent.
-- This initial patent application gives MGC Pharma priority to
file subsequent patent applications for CimetrA(TM) in other
jurisdictions and other IP agencies such as EU and WIPO.
-- MGC Pharma expects the patent for CimetrA(TM) to be issued within the next 12 months.
-- This patent sets out a novel pharmaceutical composition and
self-nanoemulsifying drug delivery system (SNEDDS).
-- CimetrA(TM) encapsulates Graft Polymer's proprietary
GraftBio(TM) SNEDDS technology (Self-Nano Emulsifying Drug Delivery
System) , a unique platform to deliver active ingredients more
effectively in higher concentrations to the cells, improving the
bioavailability and synergy of natural active ingredients.
-- MGC Pharma continues to progress towards the commencement of
its phase III clinical trial for CimetrA(TM) in order to
demonstrate the full efficacy and pharmacokinetic profile of the
treatment in different variants of the COVID-19 virus.
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the
Company'), a European based bio-pharma company specialising in the
production and development of phytocannabinoid-derived medicines,
is pleased to announce the successful submission of a patent
application for CimetrA(TM) to the Slovenian Intellectual Property
Office (SIPO), assigned to MGC Pharma.
MGC Pharma submitted its patent application which was accepted
by SIPO on 5 May 2021 (file number: P-202100096) which is the
priority date for the patent, giving the Company priority to file
subsequent patent applications for CimetrA(TM) in other
jurisdictions and to other IP Agencies such as the EU and WIPO. MGC
Pharma expects the patent to be issued within the next 12
months.
The patent provides a nano-micellular pharmaceutical synergetic
composition consisting of Curcumin, Boswellia, Artemisinin, and
optionally Cannabinoids and/or Nitroxides. The composition can be
manufactured in liquids or in solid pharmaceutically acceptable
carriers, has antioxidant, anti- inflammatory, immuno-modulating,
anti-viral and anti-cancer properties and can be designed for
multiple therapeutic applications, utilising self-nanoemulsifying
drug delivery systems (SNEDDS).
The patent sets out the specific antioxidant, anti-inflammatory,
immune-modulating, anti-viral, and anti-cancer properties of
CimetrA(TM) , designed for multiple therapeutic applications
including the treatment of chronic inflammation, severe acute
respiratory syndrome coronavirus (SARS-Covid, COVID-19) and heavy
variants of influenza, as well as various types of cancer. This is
in addition to its efficacy in relation to the regulation of the
human body's circadian rhythm and homeostasis which promotes an
immune response to bacterial, viral, fungal and parasitic
infections. It's wide range of uses as a treatment highlights its
versatility as an IMP.
Preclinical and clinical results to date support the
pharmaceutical composition of CimetrA(TM) as an effective treatment
for addressing anti-inflammation and cytokine over-production
(known as cytokine storm) in all tested COVID-19 patients.
Many plant molecules which make up the API are hydrophobic (not
water soluble) and thus cannot be readily absorbed by the body.
Once these are encapsulated within the oil-free type IV
nano-micellar SNEDDS, the bioavailability of the molecules is
increased and the API are emulsified and absorbed more efficiently,
resulting in more effective treatment.
The submission of this patent therefore has significant
implications for the pharmaceutical industry and will ultimately
help to increase general drug efficiency.
MGC Pharma is advancing the clinical development program for
CimetrA(TM) as an IMP to demonstrate the full efficacy and
pharmacokinetic profile of the treatment in relation to treating
different variants of COVID-19, through a Phase III clinical trial
that is expected to commence shortly (See 22 March 2021
announcement).
Roby Zomer, Co-founder and Managing Director of MGC Pharma,
commented: " We are delighted that the SIPO recognises the unique
formulation of CimetrA(TM) , something we believe will be
transformational in the treatment of COVID 19 as well as numerous
other conditions. The submission of this patent application is an
important next step in bringing CimetrA(TM) to market in multiple
jurisdictions and ultimately treating people and patients on a
global scale whilst Phase III trials for the IMP continue.
--Ends--
Authorised for release by the Board, for further information
please contact:
MGC Pharmaceuticals Ltd UK PR Advisors - Tavistock
Roby Zomer Tim Pearson
CEO & Managing Director +44 207 920 3150
+61 8 6382 3390 Tim.Pearson@tavistock.co.uk
info@mgcpharma.com.au
UK Broker - Turner Pope Australian IR Advisors - Media
Andy Thacker & Capital Partners
+44 203 657 0050 Rod Hinchcliffe
info@turnerpope.com +61 412 277 377
Rod.Hinchcliffe@mcpartners.com.au
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
bio-pharma company developing and supplying affordable standardised
phytocannabinoid derived medicines to patients globally. The
Company's founders were key figures in the global medical cannabis
industry and the core business strategy is to develop and supply
high quality phytocannabinoid derived medicines for the growing
demand in the medical markets in Europe, North America and
Australasia. MGC Pharma has a robust product offering targeting two
widespread medical conditions - epilepsy and dementia - and has
further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has
partnered with renowned institutions and academia to optimise
cultivation and the development of targeted phytocannabinoid
derived medicines products prior to production in the Company's
EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world
renowned academic institutions, and including recent research
highlighting the positive impact of using specific phytocannabinoid
formulations developed by MGC Pharma in the treatment of
glioblastoma, the most aggressive and so far therapeutically
resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAPGLGDUSUBDGBR
(END) Dow Jones Newswires
May 17, 2021 02:58 ET (06:58 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
